These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23072876)

  • 1. New treatment paradigms for optimizing survival in advanced and metastatic breast cancer.
    Perez EA; Burris HA; Mooberry S; Tripathy D
    Clin Adv Hematol Oncol; 2012 Aug; 10(8 Suppl 13):1-14; quiz 15-6. PubMed ID: 23072876
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical implications of intratumoral heterogeneity of HER2 gene amplification in locally advanced HER2-positive breast cancer patients.
    Hacioglu B; Akin S; Sever AR; Altundag K
    Future Oncol; 2015 Sep; 11(18):2495-7. PubMed ID: 26278702
    [No Abstract]   [Full Text] [Related]  

  • 3. Advances in anti-HER2 therapy in metastatic breast cancer.
    Yao M; Fu P
    Chin Clin Oncol; 2018 Jun; 7(3):27. PubMed ID: 30056729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting HER2 in Advanced Breast Cancer.
    Zhu X; Joy AA
    Methods Mol Biol; 2017; 1652():63-77. PubMed ID: 28791634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthracyclines and the tailoring of treatment for early breast cancer.
    Piccart-Gebhart MJ
    N Engl J Med; 2006 May; 354(20):2177-9. PubMed ID: 16707755
    [No Abstract]   [Full Text] [Related]  

  • 6. Dual HER2 blockade slows metastatic breast cancer.
    Bender E
    Cancer Discov; 2012 Jan; 2(1):OF4. PubMed ID: 22585174
    [No Abstract]   [Full Text] [Related]  

  • 7. Advances in chemotherapy for HER2-negative metastatic breast cancer.
    Mukai H; Ito M
    Chin Clin Oncol; 2018 Jun; 7(3):26. PubMed ID: 30056728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current treatment options for metastatic breast cancer: what now?
    Rugo HS; O'Shaughnessy JA; Perez EA
    Clin Adv Hematol Oncol; 2011 Nov; 9(11 Suppl 25):1-16. PubMed ID: 22362269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab emtansine for HER2-positive breast cancer.
    Venkatesan P
    Lancet Oncol; 2016 Dec; 17(12):e528. PubMed ID: 27866859
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical roundtable monograph. Current treatment options for metastatic breast cancer: what now?
    Rugo HS; O'Shaughnessy JA; Perez EA
    Clin Adv Hematol Oncol; 2011 Nov; 9(11):1-16. PubMed ID: 22355830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
    Brogdon CF; Lee FY; Canetta RM
    Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eribulin, a microtubule inhibitor for metastatic breast cancer.
    Wilkes GM
    Oncology (Williston Park); 2011 Feb; 25(2 Suppl Nurse Ed):46-8. PubMed ID: 25373284
    [No Abstract]   [Full Text] [Related]  

  • 13. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
    Baron JM; Boster BL; Barnett CM
    J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2-positive breast cancer: current treatment strategies.
    Perez EA; Baweja M
    Cancer Invest; 2008 Jul; 26(6):545-52. PubMed ID: 18584344
    [No Abstract]   [Full Text] [Related]  

  • 15. Current and future anti-HER2 therapy in breast cancer.
    Vrbic S; Pejcic I; Filipovic S; Kocic B; Vrbic M
    J BUON; 2013; 18(1):4-16. PubMed ID: 23613383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pertuzumab (Perjecta) for HER2-positive metastatic breast cancer.
    Med Lett Drugs Ther; 2012 Jul; 54(1395):59-60. PubMed ID: 22825690
    [No Abstract]   [Full Text] [Related]  

  • 18. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
    Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
    Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
    Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab.
    Eniu A
    J BUON; 2007 Sep; 12 Suppl 1():S119-26. PubMed ID: 17935269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.